Semaglutide research: the mechanism, the landmark trials, and the frontier

Start here

Semaglutide research now spans tens of thousands of trial participants and several frontiers. This page logs it in plain language, then in full.

The core idea: semaglutide copies GLP-1, a hormone your gut releases after eating that lowers blood sugar and curbs appetite. The natural hormone lasts about two minutes; semaglutide is rebuilt to last about a week, so one dose works for seven days ^[12]. Big trials show large weight loss ^[1], lower heart-attack and stroke risk ^[3], and slower kidney decline in diabetes ^[6].

The newest line is about the brain's reward system — early evidence that it can reduce alcohol drinking ^[8]. Below: what it is, how it works, the landmark trials, how it compares to tirzepatide, and the frontier.

What is semaglutide

Semaglutide is a 31-amino-acid acylated analogue of human GLP-1, sharing about 94% of its sequence with the natural hormone ^[12]. Two changes make it last: a position-8 substitution (alpha-aminoisobutyric acid) blocks the enzyme DPP-4 that normally chews up GLP-1 in minutes, and a C18 fatty-acid side chain binds tightly but reversibly to albumin (the most abundant protein in blood), which shields the drug from rapid clearance ^[12]. The net effect is an elimination half-life of about one week, with effectively complete clearance roughly five weeks after the last dose ^[12].

It belongs to the GLP-1 receptor agonist class — drugs that switch on the GLP-1 receptor to mimic the natural incretin (a gut hormone that boosts insulin after meals). It is FDA-approved, available as a once-weekly subcutaneous injection and a once-daily oral tablet ^[11].

How does semaglutide work

Three mechanisms run in parallel. First, glucose-dependent insulin secretion: it prompts the pancreas to release insulin only when blood glucose is high, which is why, on its own, it carries little hypoglycemia risk ^[12]. Second, it suppresses glucagon, the hormone that raises blood sugar ^[12]. Third, it slows gastric emptying, so food leaves the stomach more gradually ^[12].

The weight effect is largely central. A rodent study mapped how semaglutide reaches the brain directly — the brainstem, area postrema, hypothalamic arcuate nucleus, and parabrachial nucleus — where it activates satiety neurons (POMC/CART) and inhibits hunger neurons (NPY/AgRP), cutting food intake and shifting food preference without lowering energy expenditure ^[4]. That same reward circuitry is the bridge to the alcohol research below.

The landmark trials

Semaglutide weight loss

STEP 1 anchors the semaglutide weight loss record. Once-weekly semaglutide 2.4 mg produced a mean body-weight change of -14.9% from baseline to week 68 versus -2.4% on placebo in adults with overweight or obesity without diabetes (n=1,961) — a treatment difference of about 12.4 percentage points ^[1].

Cardiovascular outcomes — SUSTAIN-6 and SELECT. In SUSTAIN-6, semaglutide (0.5 or 1.0 mg weekly) reduced the composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (HR 0.74; 95% CI 0.58-0.95) in type 2 diabetes at high cardiovascular risk; the same trial recorded more diabetic-retinopathy complications (HR 1.76; 95% CI 1.11-2.78) ^[2]. In SELECT (n=17,604), semaglutide 2.4 mg cut major adverse cardiovascular events by 20% versus placebo (HR 0.80; 95% CI 0.72-0.90; P<0.001) in people with cardiovascular disease and obesity but no diabetes ^[3].

Kidney outcomes — FLOW. In type 2 diabetes with chronic kidney disease (n=3,533), semaglutide 1.0 mg weekly cut major kidney-disease events — kidney failure, a 50%-or-greater eGFR decline, or kidney/cardiovascular death — by 24% (HR 0.76; 95% CI 0.66-0.88) ^[6].

Semaglutide vs tirzepatide

The most direct comparison is SURMOUNT-5, a head-to-head obesity trial (n=751). At 72 weeks, tirzepatide — a dual GIP/GLP-1 receptor agonist — produced greater mean weight loss than semaglutide: -20.2% versus -13.7%, an advantage of about 6.5 percentage points, statistically significant (P<0.001) ^[7].

The takeaway is comparative, not dismissive. Semaglutide's 13.7% in that trial is consistent with its own STEP-program record ^[1], and its separate cardiovascular- and kidney-outcome evidence stands on its own ^[3][6]. The two drugs act through overlapping but not identical receptor targets, which is the leading explanation for the weight-loss gap.

The frontier: alcohol, reward, and body composition

Alcohol use disorder. The headline emerging finding: in a phase-2 randomized trial (n=48), low-dose semaglutide reduced laboratory alcohol self-administration (grams consumed; beta -0.48, 95% CI -0.85 to -0.11, P=0.01) and predicted greater reductions in heavy drinking over nine weeks ^[8]. A rodent study found reduced alcohol intake and modulation of central GABA neurotransmission, supporting a reward-pathway mechanism ^[9], and a review of GLP-1 receptor agonists in alcohol use disorder reads the early evidence as promising while calling for larger trials ^[10]. Detail on the semaglutide and alcohol page.

Body composition. A trial substudy reported that the weight lost includes both fat and a meaningful proportion of lean (muscle) mass — the basis for ongoing research into protein and resistance training to protect muscle ^[13]. Detail on the semaglutide muscle loss page.

Pharmacovigilance. A real-world disproportionality analysis characterized the post-marketing adverse-event profile as dominated by gastrointestinal events, with additional signals under continued surveillance ^[18].

How to read this record

Reproducibility is itself a finding. The weight effect repeats across the STEP program; the cardiovascular benefit appears in both diabetes (SUSTAIN-6) and non-diabetes (SELECT) populations ^[2][3]. The open questions are logged in plain view too: the alcohol work is early-phase and small ^[8], the lean-mass concern is an extrapolation from an observed substudy finding ^[13], and several safety signals remain unconfirmed ^[5]. Findings first, attribution after, gaps marked — not filled.